Should I Buy CVM? CVM 2026 Analysis

Should You Buy CEL-SCI Corp (CVM) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

5.870

1 Day change

-6.83%

52 Week Range

20.410

Analysis Updated At

2026/01/29

CEL-SCI Corp (CVM) is not a strong buy at the moment for a beginner investor with a long-term focus. While there are some positive catalysts, such as insider buying and upcoming clinical trials, the company's financial performance is weak, and technical indicators do not suggest a strong entry point. Given the investor's background and strategy, it is better to hold off on investing in CVM until clearer signs of growth or stability emerge.

Technical Analysis

The MACD is slightly positive at 0.132 but contracting, indicating weakening momentum. RSI is neutral at 49.944, suggesting no clear overbought or oversold conditions. Moving averages are converging, showing no strong trend. The stock is trading near its pivot point of 5.808, with key resistance at 6.515 and support at 5.102. Overall, the technical indicators do not provide a strong buy signal.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Insider buying has increased significantly, with the CEO purchasing shares recently.
The company is preparing for a confirmatory registration study for its cancer treatment Multikine, which could drive future growth.
Retail sentiment on Stocktwits is bullish, with increasing message volume.

Neutral/Negative Catalysts

The stock price dropped 6.83% in the regular market session, reflecting weak short-term sentiment.
Financial performance remains poor, with a net loss of $6.1 million in Q4 2025 and a significant EPS decline of -71.04% YoY.
No recent trading activity from Congress or other influential figures.

Financial Performance

In Q4 2025, revenue remained at $0 with no growth YoY. Net income slightly improved to -$6.1 million (-0.14% YoY), but EPS dropped significantly to -0.86 (-71.04% YoY). Gross margin remains at 0%. Overall, the financials indicate a struggling company with no immediate signs of profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes are available for CVM. Wall Street sentiment is unclear, but the lack of strong institutional interest suggests a cautious outlook.

Analyst Rating

Wall Street analysts forecast CVM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVM is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy